Pemetrexad in treating patients with locally advanced or metastatic lung adenocarcinoma

Authors

  • نادر عبدالله Tishreen University

Abstract

Chemotherapy is the primary treatment in metastatic and locally advanced  molecular biomarker negative non-small cell lung cancer. Platinum-based chemotherapy with a third-generation agent (gemcitabine, paclitaxel, docetaxel, or vinorelbine) has significantly improved median survival and quality of life in those patients

Pemetrexed in combination with platinum based therapy has recently been considered the preferred first-line treatment option in locally advanced and metastatic non-squamous non-small cell lung cancers. The aim of this retrospective study was to evaluate the efficacy of pemetrexad in patients with locally advanced or metastatic lung adenocarcinoma  in terms of recurrence-free survival.

 

The study included 47 patients who attended the Chemotherapy and Radiotherapy Center from September 2018 to April 2021 who had locally advanced and  metastatic lung adenocarcinoma. The average age of patients is 57.74 years, including 34 males and 13 females. The performance status of patients is between 0-2. 17 patients received treatment as a first line, 16 patients as a second line . and 14 patients as a third line. The combination with cisplatin was in 12 patients, with carboplatin 16 patients and 19 patients who received as monotherapy.

The average recurrence-free survival rate, regardless of the treatment line, was 6.55 months (1-24 months). The response was better when it was used as a first line of treatment. The average relapse-free survival rate was 8.59 months compared to 6.56 months as a second line and 4,07 months as the third line with a statistically significant value p = 0,025 as well as the response was better in patients with good performance status 0-1 versus 2 9.86 months compared to 3.64 months with a statistically significant value p = 0.006.While there was no statistically significant difference in effectiveness according to drug combination, gender and smoking status.

 Pemetrexad in combination with platinum based therapy is considered the best treatment option in patients with locally advanced and metastatic lung adenocarcinoma, especially in patients with a good performance status PS=0-1.

Author Biography

نادر عبدالله, Tishreen University

Associate Professor - Department of Oncology - Faculty of Human Medicine

Downloads

Published

2022-06-16

How to Cite

1.
عبدالله ن. Pemetrexad in treating patients with locally advanced or metastatic lung adenocarcinoma. Tuj-hlth [Internet]. 2022Jun.16 [cited 2024Nov.24];44(2):71-80. Available from: https://journal.tishreen.edu.sy/index.php/hlthscnc/article/view/11779

Issue

Vol. 44 No. 2 (2022): Tishreen University Journal for Research and Scientific Studies - Health Sciences Series

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series

 Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series   .  The Readers have the right to send, print and subscribe to the initial version of the article, and the title of  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series  Publisher

journal uses a CC BY-NC-SA license which mean

You are free to:

  • Adapt — remix, transform, and build upon the material
  •  
  • The licensor cannot revoke these freedoms as long as you follow the license terms.

 

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • NonCommercial — You may not use the material for commercial purposes.
  • ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.